iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024 Showcases Additional Platform Offerings
ICAD Stock | USD 1.77 0.04 2.31% |
About 55% of Icad's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding icad inc suggests that some traders are interested. The current market sentiment, together with Icad's historical and current headlines, can help investors time the market. In addition, many technical investors use icad inc stock news signals to limit their universe of possible portfolio assets.
Icad |
Clinical evidence demonstrates ProFound Detections AI may help reduce breast interval cancer rates and decrease recall rates without additional false negatives Findings reveal substantially lower radiology reading
Read at benzinga.com
Icad Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Icad can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Icad Fundamental Analysis
We analyze Icad's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icad based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Icad is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
icad inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Icad stock to make a market-neutral strategy. Peer analysis of Icad could also be used in its relative valuation, which is a method of valuing Icad by comparing valuation metrics with similar companies.
Peers
Icad Related Equities
BMRA | Biomerica | 21.88 | ||||
MOVE | Movano | 4.64 | ||||
SSKN | STRATA Skin | 3.96 | ||||
FNA | Paragon 28 | 3.20 | ||||
SIBN | Si Bone | 2.19 | ||||
SGHT | Sight Sciences | 2.05 | ||||
NVRO | Nevro Corp | 0.44 | ||||
CVRX | CVRx | 0.07 | ||||
SRDX | SurModics | 0.23 | ||||
PROF | Profound Medical | 0.37 | ||||
ESTA | Establishment Labs | 0.39 | ||||
AXGN | Axogen | 1.21 | ||||
LNSR | LENSAR | 2.08 | ||||
AIMD | Ainos | 2.08 | ||||
NVNO | EnVVeno Medical | 2.51 |
Complementary Tools for Icad Stock analysis
When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |